Braidwell LP Decreases Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Braidwell LP decreased its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 25.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 222,424 shares of the company's stock after selling 75,144 shares during the quarter. Braidwell LP owned approximately 0.18% of Vaxcyte worth $18,208,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of PCVX. Brevan Howard Capital Management LP grew its position in shares of Vaxcyte by 137.8% in the 4th quarter. Brevan Howard Capital Management LP now owns 4,393 shares of the company's stock valued at $360,000 after buying an additional 2,546 shares during the last quarter. Bridgefront Capital LLC boosted its holdings in Vaxcyte by 4.2% in the fourth quarter. Bridgefront Capital LLC now owns 4,244 shares of the company's stock valued at $347,000 after acquiring an additional 172 shares during the last quarter. Brown Advisory Inc. increased its position in Vaxcyte by 25.3% during the 4th quarter. Brown Advisory Inc. now owns 556,209 shares of the company's stock valued at $45,531,000 after purchasing an additional 112,170 shares during the period. Bayesian Capital Management LP bought a new position in Vaxcyte during the 4th quarter worth approximately $1,654,000. Finally, BNP Paribas Financial Markets acquired a new position in shares of Vaxcyte in the 4th quarter worth approximately $7,471,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Vaxcyte

In other news, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $83.85, for a total transaction of $670,800.00. Following the completion of the sale, the chief financial officer now directly owns 109,491 shares of the company's stock, valued at approximately $9,180,820.35. The trade was a 6.81 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 3.10% of the stock is currently owned by company insiders.

Vaxcyte Stock Down 0.9 %

PCVX traded down $0.29 on Friday, hitting $31.16. The company's stock had a trading volume of 2,030,375 shares, compared to its average volume of 1,306,324. The firm has a market cap of $4.02 billion, a P/E ratio of -6.77 and a beta of 1.27. The company's 50 day simple moving average is $46.66 and its 200-day simple moving average is $74.72. Vaxcyte, Inc. has a 12 month low of $27.66 and a 12 month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter in the previous year, the company earned ($0.85) EPS. Equities analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on PCVX shares. Guggenheim reaffirmed a "buy" rating and set a $160.00 price objective on shares of Vaxcyte in a research report on Wednesday, March 12th. Bank of America cut their price objective on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Needham & Company LLC restated a "buy" rating and set a $90.00 price target on shares of Vaxcyte in a report on Tuesday, April 8th. The Goldman Sachs Group cut their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Finally, Cantor Fitzgerald started coverage on Vaxcyte in a research report on Tuesday, April 22nd. They issued an "overweight" rating on the stock. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $136.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.